Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2014
09/18/2014WO2014140376A1 Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
09/18/2014WO2014140330A1 Anti-ddr1 internalizing antibodies and their medical use
09/18/2014WO2014140322A1 Novel medicaments comprising an antibody composition enriched with predominant charge isoform
09/18/2014WO2014140301A1 Anti-mycobacterial vaccines
09/18/2014WO2014140239A1 Liquid stable bovine virus vaccines
09/18/2014WO2014140210A1 Novel binding proteins for pcsk9
09/18/2014WO2014140190A1 Rsv vaccines
09/18/2014WO2014140176A1 Targeting vaccines for veterinary use
09/18/2014WO2014140166A2 Vaccine
09/18/2014WO2014139687A1 Single high dose of mva induces a protective immune response in neonates and infants
09/18/2014WO2014139672A1 Her2/neu cancer vaccine
09/18/2014WO2014139587A1 Improved poxviral vaccines
09/18/2014WO2014139539A1 Inhibitor of dpysl3/crmp4 for treatment of bone loss
09/18/2014WO2014139476A1 Epitope of rsv fusion protein and antibody identifying same
09/18/2014WO2014139425A1 Anti-blys monoclonal antibody and pharmaceutical composition containing antibody
09/18/2014WO2014139359A1 Hepatitis b vaccine
09/18/2014WO2014139131A1 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
09/18/2014WO2014139014A1 Methods and compositions for the inhibition of vascular endothelial growth factor activity and vascular permeability
09/18/2014WO2014138924A1 Compositions and methods for treating clostridium difficile-associated diseases
09/18/2014WO2014138862A1 Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
09/18/2014WO2014138824A1 Immune modulation
09/18/2014WO2014138819A1 Agents that neutralize il-3 signaling and uses thereof
09/18/2014WO2014138805A1 Anti il-3r alpha agents and uses thereof
09/18/2014US20140275509 Multifunctionalized materials
09/18/2014US20140275478 Vaccines against Chlamydia sp.
09/18/2014US20140271889 Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
09/18/2014US20140271836 Manufacture of peanut formulations for oral desensitization
09/18/2014US20140271827 Lipid vesicle compositions and methods of use
09/18/2014US20140271817 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
09/18/2014US20140271815 Heat-and freeze-stable vaccines and methods of making and using same
09/18/2014US20140271800 Immune modulation using peptides and other compositions
09/18/2014US20140271725 Small Molecule Enhancer for Dendritic Cell Cancer Vaccines
09/18/2014US20140271724 Methods and compositions for treating or preventing cancer
09/18/2014US20140271723 Adjuvant compositions and methods of using thereof
09/18/2014US20140271722 Allergen dosage form
09/18/2014US20140271721 Peanut formulations and uses thereof
09/18/2014US20140271720 Method of Treating Fungal Infection
09/18/2014US20140271718 Novel type 1 diabetes vaccines, and methods of use
09/18/2014US20140271716 Intra-testicular Injection of Immunogens
09/18/2014US20140271715 Compositions and methods for live, attenuated alphavirus formulations
09/18/2014US20140271714 Induction of an immune response against dengue virus using the prime-boost approach
09/18/2014US20140271713 Method for keeping a food and mouth disease vaccine available for emergency vaccination
09/18/2014US20140271710 Liquid stable bovine virus vaccines
09/18/2014US20140271709 Bovine virus vaccines that are liquid stable
09/18/2014US20140271708 Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
09/18/2014US20140271702 Vaccination of Companion Animals to Elicit a Protective Immune Response Against Tick Infestations and Tick-Borne Pathogen Transmission
09/18/2014US20140271700 Compositions and methods for treating clostridium difficile-associated diseases
09/18/2014US20140271698 Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
09/18/2014US20140271697 Enhanced expression of picornavirus proteins
09/18/2014US20140271696 Heat-Stable Respiratory Syncytial Virus F Protein Oligomers and Their Use in Immunological Compositions
09/18/2014US20140271695 Immunogenic lhrh compositions and methods relating thereto
09/18/2014US20140271692 Novel immunogenic epitopes for immunotherapy
09/18/2014US20140271691 Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
09/18/2014US20140271689 Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase)
09/18/2014US20140271688 Antibody drug conjugates
09/18/2014US20140271684 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
09/18/2014US20140271683 Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
09/18/2014US20140271681 High Affinity Human Antibodies to Human IL-4 Receptor
09/18/2014US20140271677 Newcastle Disease Viruses and Uses Thereof
09/18/2014US20140271673 Use of lxr antagonists for treatment of side effects of elevated glucocorticoid levels
09/18/2014US20140271670 Compositions for treating skin disorders
09/18/2014US20140271669 Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
09/18/2014US20140271667 Methods and Compositions for Neoadjuvant Therapy
09/18/2014US20140271665 Combinations of Kinase Inhibitors for the Treatment of Cancer
09/18/2014US20140271664 Therapeutic use of antibodies to hgf
09/18/2014US20140271661 Monoclonal antibodies against antithrombin beta
09/18/2014US20140271660 Monoclonal antibodies against antithrombin beta
09/18/2014US20140271658 Anti-il-33 antibodies and uses thereof
09/18/2014US20140271657 Combinatorial compositions and methods of treating hemoglobinopathies
09/18/2014US20140271656 Optimized antigens of pneumocystis and use thereof
09/18/2014US20140271654 Methods for treating bone gap defects
09/18/2014US20140271653 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
09/18/2014US20140271650 Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
09/18/2014US20140271649 Methods and compositions for inhibiting staphylococcus agglutination in blood
09/18/2014US20140271645 Method for treating inflammation
09/18/2014US20140271644 Combination/adjuvant therapy for wt-1-positive disease
09/18/2014US20140271642 Il-33 antagonists and uses thereof
09/18/2014US20140271638 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
09/18/2014US20140271637 Methods of administering anti-tnfalpha antibodies
09/18/2014US20140271634 Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
09/18/2014US20140271630 Rituximab induction therapy followed by glatiramer acetate therapy
09/18/2014US20140271625 Methods for treating bleeding disorders
09/18/2014US20140271624 Anti-notch nrr antibodies and methods using same
09/18/2014US20140271620 Modified hyaluronan and uses thereof in cancer treatment
09/18/2014US20140271619 Cd20 conformational isomers and methods of using
09/18/2014US20140271618 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
09/18/2014US20140271613 Surgical Compositions
09/18/2014US20140271541 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
09/18/2014US20140271501 Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
09/18/2014US20140271459 Antibodies to hgf and compositions containing
09/17/2014EP2778175A1 Humanized anti-interleukin 3 receptor alpha chain antibodies for use in treating acute myeloid leukemia (AML)
09/17/2014EP2777712A1 Adjuvants for polysaccharide vaccines and resulting formulations
09/17/2014EP2777711A1 Her2/Neu cancer vaccine
09/17/2014EP2776567A2 Compositions and methods for treatment of cytomegalovirus
09/17/2014EP2776469A2 Antibody molecules having specificity for human ox40
09/17/2014EP2776468A2 Methods of inhibiting tumor growth by antagonizing il-6 receptor
09/17/2014EP2776467A1 Methods of treating inflammatory disorders using anti-m-csf antibodies
09/17/2014EP2776463A1 Neutralizing gp41 antibodies and their use
09/17/2014EP2776069A1 Carrier molecule comprising a spr0096 and a spr2021 antigen
09/17/2014EP2776066A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
1 ... 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 ... 1823